194 related articles for article (PubMed ID: 35990956)
21. Alcohol consumption and atrial fibrillation risk: An updated dose-response meta-analysis of over 10 million participants.
Jiang H; Mei X; Jiang Y; Yao J; Shen J; Chen T; Zhou Y
Front Cardiovasc Med; 2022; 9():979982. PubMed ID: 36247447
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Utility of Circulating Growth Factors in Aortic Valve Stenosis: A Pilot Study.
Hofmanis J; Tretjakovs P; Svirskis S; Gersone G; Hofmane D; Rozenberga U; Blumfelds L; Bahs G; Lejnieks A; Mackevics V
Medicina (Kaunas); 2021 Jan; 57(1):. PubMed ID: 33477548
[No Abstract] [Full Text] [Related]
23. A systematic review and meta-analysis of the gut microbiota-dependent metabolite trimethylamine N-oxide with the incidence of atrial fibrillation.
Yang WT; Yang R; Zhao Q; Li XD; Wang YT
Ann Palliat Med; 2021 Nov; 10(11):11512-11523. PubMed ID: 34872276
[TBL] [Abstract][Full Text] [Related]
24. Growth differentiation factor-15 predicts major adverse cardiac events and all-cause mortality in patients with atrial fibrillation.
Nopp S; Königsbrügge O; Kraemmer D; Pabinger I; Ay C
Eur J Intern Med; 2021 Jun; 88():35-42. PubMed ID: 33706979
[TBL] [Abstract][Full Text] [Related]
25. Influenza vaccination is associated with a decreased risk of atrial fibrillation: A systematic review and meta-analysis.
Liu M; Lin W; Song T; Zhao H; Ma J; Zhao Y; Yu P; Yan Z
Front Cardiovasc Med; 2022; 9():970533. PubMed ID: 36337907
[TBL] [Abstract][Full Text] [Related]
26. Accuracy of FGF-21 and GDF-15 for the diagnosis of mitochondrial disorders: A meta-analysis.
Lin Y; Ji K; Ma X; Liu S; Li W; Zhao Y; Yan C
Ann Clin Transl Neurol; 2020 Jul; 7(7):1204-1213. PubMed ID: 32585080
[TBL] [Abstract][Full Text] [Related]
27. Plasma growth differentiation factor-15 in patients with "lone" atrial fibrillation.
Li N; Feng Q; Yu F; Zhou J; Guo X
J Clin Lab Anal; 2022 May; 36(5):e24373. PubMed ID: 35334497
[TBL] [Abstract][Full Text] [Related]
28. Association Between Omega-3 Fatty Acid Treatment and Atrial Fibrillation in Cardiovascular Outcome Trials: A Systematic Review and Meta-Analysis.
Jia X; Gao F; Pickett JK; Al Rifai M; Birnbaum Y; Nambi V; Virani SS; Ballantyne CM
Cardiovasc Drugs Ther; 2021 Aug; 35(4):793-800. PubMed ID: 34057665
[TBL] [Abstract][Full Text] [Related]
29. N-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials.
Mariani J; Doval HC; Nul D; Varini S; Grancelli H; Ferrante D; Tognoni G; Macchia A
J Am Heart Assoc; 2013 Feb; 2(1):e005033. PubMed ID: 23525440
[TBL] [Abstract][Full Text] [Related]
30. The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure.
Santema BT; Chan MMY; Tromp J; Dokter M; van der Wal HH; Emmens JE; Takens J; Samani NJ; Ng LL; Lang CC; van der Meer P; Ter Maaten JM; Damman K; Dickstein K; Cleland JG; Zannad F; Anker SD; Metra M; van der Harst P; de Boer RA; van Veldhuisen DJ; Rienstra M; Lam CSP; Voors AA
Clin Res Cardiol; 2020 Mar; 109(3):331-338. PubMed ID: 31263996
[TBL] [Abstract][Full Text] [Related]
31. Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial.
Oyama K; Giugliano RP; Berg DD; Ruff CT; Jarolim P; Tang M; Murphy SA; Lanz HJ; Grosso MA; Antman EM; Braunwald E; Morrow DA
Eur Heart J; 2021 May; 42(17):1698-1706. PubMed ID: 33760027
[TBL] [Abstract][Full Text] [Related]
32. Increased plasma levels of NT-proBNP, Troponin T and GDF-15 are driven by persistent AF and associated comorbidities: Data from the AF-RISK study.
Meems LMG; Artola Arita V; Velt M; Dudink EAMP; Crijns HJGM; Van Gelder IC; Rienstra M
Int J Cardiol Heart Vasc; 2022 Apr; 39():100987. PubMed ID: 35281756
[TBL] [Abstract][Full Text] [Related]
33. Blood lipid profiles and risk of atrial fibrillation: A systematic review and meta-analysis of cohort studies.
Guan B; Li X; Xue W; Tse G; Waleed KB; Liu Y; Zheng M; Wu S; Xia Y; Ding Y
J Clin Lipidol; 2020; 14(1):133-142.e3. PubMed ID: 31926850
[TBL] [Abstract][Full Text] [Related]
34. Influence of the matrix type over the concentration of GDF-15.
Rivera-Caravaca JM; Vílchez JA; Rodríguez-Rojas C; Albadalejo-Otón MD; Gil-Pérez P; Lopez-García C; Veliz-Martínez A; Roldán V; Marín F
J Investig Med; 2020 Dec; 68(8):1402-1404. PubMed ID: 32907909
[TBL] [Abstract][Full Text] [Related]
35. Relationship between serum uric acid levels and different types of atrial fibrillation: An updated meta-analysis.
Wang X; Hou Y; Wang X; Li Z; Wang X; Li H; Shang L; Zhou J; Zhang Y; Ren M; Zhang Y
Nutr Metab Cardiovasc Dis; 2021 Sep; 31(10):2756-2765. PubMed ID: 34348878
[TBL] [Abstract][Full Text] [Related]
36. A comparison of current serum biomarkers as diagnostic indicators of mitochondrial diseases.
Davis RL; Liang C; Sue CM
Neurology; 2016 May; 86(21):2010-5. PubMed ID: 27164684
[TBL] [Abstract][Full Text] [Related]
37. GDF-15 Is Elevated in Children with Mitochondrial Diseases and Is Induced by Mitochondrial Dysfunction.
Montero R; Yubero D; Villarroya J; Henares D; Jou C; Rodríguez MA; Ramos F; Nascimento A; Ortez CI; Campistol J; Perez-Dueñas B; O'Callaghan M; Pineda M; Garcia-Cazorla A; Oferil JC; Montoya J; Ruiz-Pesini E; Emperador S; Meznaric M; Campderros L; Kalko SG; Villarroya F; Artuch R; Jimenez-Mallebrera C
PLoS One; 2016; 11(2):e0148709. PubMed ID: 26867126
[TBL] [Abstract][Full Text] [Related]
38. Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
Hijazi Z; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Yusuf S; Siegbahn A; Wallentin L
Am Heart J; 2017 Aug; 190():94-103. PubMed ID: 28760218
[TBL] [Abstract][Full Text] [Related]
39. Early rhythm control vs. rate control in atrial fibrillation: A systematic review and meta-analysis.
Han S; Jia R; Cen Z; Guo R; Zhao S; Bai Y; Xie M; Cui K
Front Cardiovasc Med; 2023; 10():978637. PubMed ID: 36815025
[TBL] [Abstract][Full Text] [Related]
40. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Wallentin L; Hijazi Z; Andersson U; Alexander JH; De Caterina R; Hanna M; Horowitz JD; Hylek EM; Lopes RD; Asberg S; Granger CB; Siegbahn A;
Circulation; 2014 Nov; 130(21):1847-58. PubMed ID: 25294786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
